Tullious Stoudemayer, MD
Family Medicine · Travelers Rest, SCNPI 1538225222
Payments from drug & device makers
Across 161 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$395
- Novartis$264
- AstraZeneca$212
- Amgen$193
- AbbVie$140
- Boehringer Ingelheim$113
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,420100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $395 |
| Novartis | 16 | $264 |
| AstraZeneca | 16 | $212 |
| Amgen | 12 | $193 |
| AbbVie(2 entities) | 10 | $140 |
| Boehringer Ingelheim | 8 | $113 |
| GSK | 8 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $95 |
| Abbott | 4 | $83 |
| Dexcom, Inc. | 5 | $78 |
| Bayer | 5 | $71 |
| Lilly USA, LLC | 5 | $64 |
| Philips North America LLC | 2 | $56 |
| Amarin Pharma, Inc. | 4 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| Pfizer | 3 | $39 |
| Sunovion Pharmaceuticals Inc. | 3 | $29 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Upsher-smith Laboratories LLC | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Shire North American Group Inc | 2 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Renalytix AI, Inc. | 1 | $18 |
| Bausch Health US, LLC | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Nevro Corp. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Cequr Corporation | 1 | $13 |
| Merck | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$2,420 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $62,548 |
| OzempicSemaglutide | 47 | $50,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $48,854 |
| JardianceEmpagliflozin | 51 | $45,671 |
| TrulicityDulaglutide | 18 | $35,723 |
| XareltoRivaroxaban | 31 | $34,929 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $33,154 |
| LinzessLinaclotide | 31 | $31,957 |
| RybelsusSemaglutide | 21 | $24,400 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $20,961 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $17,992 |
| Lamictal XrLamotrigine | 12 | $16,412 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $9,744 |
| JanuviaSitagliptin Phosphate | 11 | $9,380 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $8,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $395 | $74,71968 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $109 | $69,815104 claims |
| PfizerEliquis | $39 | $62,54857 claims |
| Boehringer IngelheimJardiance | $113 | $45,67151 claims |
| Lilly USA, LLCTrulicity | $64 | $35,72318 claims |
| AbbVieLinzess | $140 | $31,95731 claims |
| MerckJanuvia | $13 | $9,38011 claims |
| AstraZenecaSymbicort | $212 | $6,16412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Travelers Rest
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.